{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'seizure', 'severe hypotension', 'other neurological symptoms (confusion, loss of consciousness, paresthesia, paralysis,', 'etc.)', 'any other symptom or sign that, in the opinion of the investigator, warrants', 'discontinuation of the infusion', '8.8.', 'Method of Treatment Assignment', 'Approximately 590 patients will be randomized in a 1:1 ratio to receive either cemiplimab or IC', 'of chemotherapy, according to a central randomization scheme provided by an interactive voice', 'response system (IVRS)/interactive web response system (IWRS) to the designated study', 'pharmacist (or qualified designee). Randomization will be stratified according to:', '1. Histology (squamous cell carcinoma versus adenocarcinoma). Adenosquamous histology', 'be considered adenocarcinoma for purposes of stratification.', '2.', 'Geographic Region: North America versus Asia versus Rest of World (ROW)', '3. Prior bevacizumab (yes/no)', '4. ECOG performance status (0,1)', 'The stratification factors of \"prior bevacizumab use\" and \"ECOG performance status\" are used for', 'balancing treatment assignment only and will not be included in the statistical model for analysis', 'of the primary endpoint.', 'After it is confirmed that the patient meets all eligibility criteria, she will be enrolled in IVRS. The', 'following information must be provided at time of enrollment, prior to randomization:', 'Patient number', 'Date of birth', 'Histology (squamous cell carcinoma versus adenocarcinoma). Adenosquamous', 'histology will be considered adenocarcinoma for purposes of stratification and', 'analysis. Starting with Amendment 5, only squamous cell patients will be enrolled', 'Geographic region', 'Prior bevacizumab (yes/no)', 'ECOG performance status (0,1)', \"Choice of Investigator's Choice treatment\", 'After a patient is enrolled in IWRS with this information, she will be randomized (1:1) to either', \"cemiplimab or Investigator's Choice of chemotherapy.\", '8.8.1.', 'Blinding', 'Not applicable.', 'Regeneron Pharmaceuticals, Inc.', 'Page 85 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '8.9.', 'Treatment Logistics and Accountability', '8.9.1.', 'Packaging, Labeling, and Storage', 'Open-label study drug will display the product lot number on the label.', 'Cemiplimab will be stored at the site at a temperature of 2\u00b0C to 8\u00b0C; storage instructions will be', 'provided in the pharmacy manual.', '8.9.2.', 'Supply and Disposition of Treatments', 'Cemiplimab will be shipped at a temperature of 2\u00b0C to 8\u00b0C to the investigator or designee at regular', 'intervals or as needed during the study. At specified time points during the study (eg, interim site', 'monitoring visits), at the site close-out visit, and following drug reconciliation and documentation', 'by the site monitor, all opened and unopened cemiplimab will be destroyed or returned to the', 'sponsor or designee.', '8.9.3.', 'Treatment Accountability', 'All drug accountability records must be kept current.', 'The investigator must be able to account for all opened and unopened cemiplimab. These records', 'should contain the dates, quantity, and study medication', 'dispensed to each patient,', 'returned from each patient (if applicable), and', 'disposed of at the site or returned to the sponsor or designee', 'All accountability records must be made available for inspection by the sponsor and regulatory', 'agency inspectors; photocopies must be provided to the sponsor at the conclusion of the study.', '8.9.4.', 'Treatment Compliance', 'All drug compliance records must be kept current and made available for inspection by the sponsor', 'and regulatory agency inspectors.', '8.10.', 'Concomitant Medications and Procedures', 'Any treatment administered, other than anti-cancer therapy, from the time of informed consent', 'until 90 days after the last study treatment will be considered concomitant treatment. This includes', 'medications and other therapies for which administration started before the study and will continue', 'during the study, as well as any therapies started in the follow-up period to treat a study drug-', 'related AE. All concomitant treatments must be recorded in the study CRF with the generic name,', 'dose, dose unit, frequency, indication, and start/stop date, as appropriate.', '8.10.1.', 'Prohibited Medications and Procedures', 'While participating in this study, a patient may not receive any anti-cancer treatment other than', 'the treatment assigned at randomization: cemiplimab or IC of chemotherapy. Patients must not', 'receive live vaccines during the study and for up to 5 half-lives after the last dose of study drug.', \"Any other medication which is considered necessary for the patient's welfare, and which is not\", 'Regeneron Pharmaceuticals, Inc.', 'Page 86 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}